BRUSSELS — UCB announced that it will add two members to its executive committee, effective July 1.

The drug maker said that Greg Duncan, currently SVP and president of UCB’s North American operations, and Jean-Christophe Tellier, who is joining the company from Ipsen, now are the heads of the U.S. and European commercial operations, respectively.

These additions will allow Mark McDade, UCB’s EVP global operations and COO, to focus on UCB’s future growth markets outside the United States and Europe, while driving UCB’s commercial growth strategy across all markets, the company said.